Auris Medical Holding Ltd represents values of innovation, excellence, and patient-centricity. With a corporate philosophy focused on developing novel therapeutics for inner ear disorders and hearing loss, the company aims to improve the lives of individuals worldwide. Through its extensive research and development efforts, Auris Medical Holding Ltd strives to bring innovative treatments to market, addressing unmet medical needs and providing hope for those suffering from hearing-related conditions. By placing patients at the center of its mission, the company contributes to enhancing the quality of life by restoring or preserving hearing capabilities. Auris Medical Holding Ltd's commitment to cutting-edge research and patient well-being drives its vision for a world with improved auditory health.

Auris Medical Holding Ltd is primarily present in several countries and regions. The company has a global presence with a focus on key markets such as the United States, Europe, and Asia. In the United States, Auris Medical Holding Ltd operates through its subsidiary, AM-Pharma, while also having a strong presence in European countries like Germany and Switzerland. The company's expansion into the Asian market includes partnerships and collaborations for drug development and commercialization. With a diversified geographical presence, Auris Medical Holding Ltd aims to cater to a wide range of investors and maximize growth opportunities across different regions.

Auris Medical Holding Ltd has achieved significant milestones in its journey. The company successfully conducted Phase 3 clinical trials for its flagship product AM-101, a potential treatment for tinnitus. This marked a major achievement, as positive results were observed in patients suffering from acute inner ear tinnitus. Auris Medical Holding Ltd also received an FDA Breakthrough Therapy designation for AM-111, another product targeting acute inner ear hearing loss. These milestones highlight the company's commitment to developing innovative solutions for hearing-related disorders. With its groundbreaking research and development efforts, Auris Medical Holding Ltd continues to make remarkable strides in the field.

Auris Medical Holding Ltd is a pharmaceutical company founded in 2003 and headquartered in Hamilton, Bermuda. The company focuses on developing novel therapies for the treatment of inner ear disorders and hearing loss. Auris Medical is dedicated to improving the lives of patients through innovative research and development in the field of otolaryngology (ENT). With a team of experienced professionals and strong collaborations, the company aims to bring safe and effective treatments to market. Auris Medical Holding Ltd is committed to advancing medical knowledge and technologies to address the unmet needs of individuals with hearing-related conditions.

The main competitors of Auris Medical Holding Ltd in the market are XYZ Corporation and ABC Inc.

Auris Medical Holding Ltd is primarily active in the healthcare industry.

The business model of Auris Medical Holding Ltd revolves around developing and commercializing therapeutic solutions for hearing loss and tinnitus. With a focus on the inner ear, Auris Medical aims to address unmet medical needs and provide innovative treatments for these conditions. By leveraging its expertise in the field of otology, the company is dedicated to advancing its portfolio of pharmaceutical products. Auris Medical's business strategy involves conducting clinical trials, obtaining regulatory approvals, and fostering strategic collaborations to bring its therapies to patients worldwide.

De K/W-verhouding kan momenteel niet worden berekend voor Auris Medical Holding.

De KUV kan momenteel niet worden berekend voor Auris Medical Holding.

De AlleAktien Kwaliteitsscore voor Auris Medical Holding is 1/10.

De omzet kan momenteel niet worden berekend voor Auris Medical Holding.

De winst kan momenteel niet berekend worden voor Auris Medical Holding.

Auris Medical Holding Ltd is a biopharmaceutical company focused on developing therapies for ear and brain diseases. The company's main divisions include research and development, marketing and sales of products, and collaboration with partners and research institutions. Auris Medical's research and development unit collaborates closely with leading scientists and clinical experts using advanced technologies and methods to develop effective therapies for ear and brain diseases. The company's key products include therapies for tinnitus and hearing loss, as well as diagnostic devices to determine the underlying causes of these conditions. Auris Medical aims to market and sell its products globally to meet the needs of patients. By collaborating with partners and research institutions, Auris Medical can develop effective therapies and explore innovative technologies. The company also works with governments and nonprofit organizations to advance research and development in the field of ear and brain diseases.

Auris Medical Holding keert een dividend van 0 CHF uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Auris Medical Holding of het bedrijf keert geen dividend uit.

De ISIN van Auris Medical Holding is BMG070252017.

Het WKN van Auris Medical Holding is A2PJN3.

De ticker van Auris Medical Holding is EARS.

Binnen de laatste 12 maanden betaalde Auris Medical Holding een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Auris Medical Holding naar verwachting een dividend van 0 CHF betalen.

De dividendrendement van Auris Medical Holding is momenteel .

Auris Medical Holding betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Auris Medical Holding betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 CHF verwacht. Dit komt overeen met een dividendrendement van 0 %.

Auris Medical Holding wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Auris Medical Holding van 20-1-2025 ter hoogte van 0 CHF te ontvangen, moest je het aandeel voor de ex-datum op 20-1-2025 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 20-1-2025.

In het jaar 2024 heeft Auris Medical Holding 0 CHF aan dividenden uitgekeerd.

De dividenden van Auris Medical Holding worden in CHF uitgekeerd.